CSTL (Castle Biosciences) EBIT per Share : $0.74 (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Castle Biosciences EBIT per Share?

Castle Biosciences's EBIT per Share for the three months ended in Dec. 2024 was $0.26. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.74.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Castle Biosciences's EBIT per Share or its related term are showing as below:

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Castle Biosciences was 32.30% per year. The lowest was -94.20% per year. And the median was -64.20% per year.

CSTL's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 4.35
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Castle Biosciences's EBIT for the three months ended in Dec. 2024 was $8.0 Mil.

Castle Biosciences EBIT per Share Historical Data

The historical data trend for Castle Biosciences's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Castle Biosciences EBIT per Share Chart

Castle Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-0.40

-1.59

-2.64

-2.14

0.76

Castle Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.09	-0.09	0.28	0.29	0.26

Castle Biosciences EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Castle Biosciences's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	22.141	/	29.255
=	0.76

Castle Biosciences's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	7.977	/	30.506
=	0.26

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.74

Castle Biosciences (NAS:CSTL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Castle Biosciences EBIT per Share Related Terms

Thank you for viewing the detailed overview of Castle Biosciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Castle Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Castle Biosciences Inc (NAS:CSTL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

505 South Friendswood Drive, Suite 401, Friendswood, TX, USA, 77546

Website

https://www.castlebiosciences.com

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Executives

Derek J Maetzold	director, 10 percent owner, officer: Pres. & Chief Exec. Officer	820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Frank Stokes	officer: Chief Financial Officer	C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Tobin W Juvenal	officer: Chief Commercial Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Kristen M Oelschlager	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Ellen Goldberg	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Tiffany Olson	director	C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Bernhard E. Spiess	officer: Chief Operating Officer	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Kim Caple	director	C/O BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
David S Kabakoff	director, 10 percent owner	C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Cook Joseph C. Iii	director, 10 percent owner	C/O CASTLE BIOSCIENCES, INC., 820 S. FRIENDSWOOD DRIVE, STE. 201, FRIENDSWOOD TX 77546
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Bonnie H Anderson	director	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mgc Venture Partners 2013 Gp, Llc	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203
Mgc Venture Partners 2013, L.p.	10 percent owner	C/O MOUNTAIN GROUP CAPITAL, LLC, 3835 CLEGHORN AVE., SUITE 300, NASHVILLE TN 37203